|Articles|November 1, 2001

Glaucoma Drug Comparison Shows IOP-Lowering Effect

Memphis, TN-Travoprost ophthalmic solution (Travatan, Alcon) has been shown to be equal or superior to latanoprost (Xalatan, Pharmacia) and superior to timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension, according to a recent study.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!

Latest CME

Virtual Event

The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

December 9, 2025

Multimedia

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Arshad M. Khanani, MD, MA, FASRS; Carl J. Danzig, MD, FASRS; Jennifer I. Lim, MD, FARVO

Multimedia

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Jacqueline Theis, OD, FAAO; Cecelia Koetting, OD, FAAO, DipABO; Melissa Barnett, OD, FAAO, FSLS, FBCLA

Multimedia

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Jacqueline Theis, OD, FAAO; Cecelia Koetting, OD, FAAO, DipABO; Melissa Barnett, OD, FAAO, FSLS, FBCLA

Multimedia

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Mitch Ibach, OD, FAAO; Jessica Steen, OD, FAAO

Multimedia

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Mitch Ibach, OD, FAAO; Jessica Steen, OD, FAAO

Glaucoma Drug Comparison Shows IOP-Lowering Effect

Newsletter

Latest CME

The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

EnVision Summit

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

Practical Approaches to Modern Dry Eye Treatment and Management

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

20th Annual Controversies in Modern Eye Care

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Collaborative Care Symposium

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt

Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD

First patient treated in ViaLase’s IDE trial

Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007

Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD